Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
Authors
Keywords
Advanced solid tumors, Chiauranib, Dose-escalation, Pharmacokinetics, Phase I study, Safety
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-14
DOI
10.1186/s13045-018-0695-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting tumour microenvironment by tyrosine kinase inhibitor
- (2018) Hor-Yue Tan et al. Molecular Cancer
- A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
- (2016) Klaus Mross et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
- (2015) Graham P. Collins et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
- (2015) Guillermo Garcia-Manero et al. INVESTIGATIONAL NEW DRUGS
- Targeting cancer with kinase inhibitors
- (2015) Stefan Gross et al. JOURNAL OF CLINICAL INVESTIGATION
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
- (2015) William D. Tap et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome
- (2014) Heather Yvonne Small et al. CANADIAN JOURNAL OF CARDIOLOGY
- Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab
- (2014) Jim Zhong et al. CANCER
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors
- (2014) Gerald S. Falchook et al. INVESTIGATIONAL NEW DRUGS
- Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study
- (2014) Gerald Falchook et al. INVESTIGATIONAL NEW DRUGS
- A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
- (2014) Christian Dittrich et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Influence of tumour micro-environment heterogeneity on therapeutic response
- (2013) Melissa R. Junttila et al. NATURE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2012) Bassam Estfan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
- (2010) J. R. Diamond et al. CLINICAL CANCER RESEARCH
- Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker
- (2010) Emily S. Robinson et al. SEMINARS IN NEPHROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started